CSPC Pharmaceutical Group (HKG:1093) obtained clinical trial approval for JMT202 from the US Food and Drug Administration, a Friday Hong Kong bourse filing said.
The drug, which is currently undergoing trials in China, can potentially be used to treat metabolism-related diseases such as dyslipidemia, metabolic dysfunction-associated steatohepatitis, type 2 diabetes, and obesity.
The indication for this approval to conduct clinical trials in the US is hypertriglyceridemia.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。